Prescribing statins to patients with nonalcoholic fatty liver disease: Real cardiovascular benefits outweigh theoretical hepatotoxic risk

Cardiovascular Therapeutics

Volumn 27, Issue 3, 2009, Pages 216-220

  Riley, P ^a   Al Bakir, M ^a   O'Donohue, J ^a   Crook, M ^a  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

Cardiovascular risk; Hepatotoxicity; Metabolic syndrome; NAFLD; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG DOSE INCREASE; DRUG SAFETY; HUMAN; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; TREATMENT WITHDRAWAL;

DRUG PRESCRIPTIONS; FATTY LIVER; GUIDELINES AS TOPIC; HEMODYNAMICS; HEPATITIS, TOXIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK;

EID: 68849103648     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00088.x     Document Type: Review

References (42)

1. Preiss D, Sattar N. Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008 115 : 141 150.
2. Lall CG, Aisen AM, Bansal N, Sandrasegaran K. Nonalcoholic fatty liver disease. AJR Am J Roentgenol 2008 190 : 993 1002.
3. Oh MK, Winn J, Poordad F. Review article: Diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008 28 : 503 522.
4. Morisco F, Pagliaro L, Caporaso N, et al. Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: Suggestions for diagnostic procedures and monitoring. Dig Liver Dis 2008 40 : 585 598.
5. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008 134 : 1682 1698.
6. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008 24 : 320 327.
7. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000 85 (12A 15E 19E.
8. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr Opin Lipidol 2002 13 : 637 644.
9. Gotto AM Jr. Safety and statin therapy: Reconsidering the risks and benefits. Arch Intern Med 2003 163 : 657 659.
10. Chalasani N. Statins and hepatotoxicity: Focus on patients with fatty liver. Hepatology 2005 41 : 690 695.
11. Joint Formulary Committee editor. British National Formulary. 54th ed. London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 2007.
12. Jacobson TA. Statin safety: Lessons from new drug applications for marketed statins. Am J Cardiol 2006 97 (8A 44C 51C.
13. Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use Am J Cardiol 2004 94 (9A 30F 34F.
14. Tolman KG. The liver and lovastatin. Am J Cardiol 2002 89 : 1374 1380.
15. Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006 97 (8A 77C 81C.
16. McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006 97 (8A 89C 94C.
17. Buse J. Statin treatment in diabetes mellitus. Clin Diabetes 2003 21 : 168 172.
18. Pasternak RC, Smith SC Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACCAHANHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002 40 : 567 572. (Pubitemid 34833176)
19. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005 118 : 618 624.
20. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005 39 (4 Suppl 2 S83 S89.
21. Dujovne CA. Side effects of statins: Hepatitis versus "transaminitis"-myositis versus "CPKitis". Am J Cardiol 2002 89 : 1411 1413.
22. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004 126 : 1287 1292.
23. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005 329 : 62 65.
24. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: Results of a pilot study. Atherosclerosis 2004 174 : 193 196.
25. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. J Hepatol 2007 47 : 135 141.
26. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike Results of a preliminary study. J Gastrointestin Liver Dis 2007 16 : 39 46.
27. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003 17 : 713 718.
28. Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004 23 : 131 134.
29. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Statins for non-alcoholic fatty liver disease: A new indication Aliment Pharmacol Ther 2006 24 : 698 699.
30. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006 184 : 233 234.
31. Schaefer EJ, Asztalos BF. The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 2006 8 : 41 49.
32. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver - An additional and treatable feature of the insulin resistance syndrome. QJM 1999 92 : 73 79.
33. Yamamoto A, Hoshi K, Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol 1998 361 : 143 149.
34. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering - Are they clinically relevant Eur Heart J 2003 24 : 225 248.
35. Dunzendorfer S, Rothbucher D, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997 81 : 963 969.
36. Vasudevan AR, Hamirani YS, Jones PH. Safety of statins: Effects on muscle and the liver. Cleve Clin J Med 2005 72 : 990 993, 996 1001.
37. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: A subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 2004 14 : 215 224.
38. Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007 11 : 597 613.
39. Chan HL, de Silva HJ, Leung NW, Lim SG, Farrell GC, Asia-Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease in 2007 J Gastroenterol Hepatol 2007 22 : 801 808.
40. Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 1994 39 : 2032 2033.
41. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 1999 94 : 1388 1390.
42. Wierzbicki AS, Crook MA. Cholestatic liver dysfunction. Lancet 1999 354 : 954.